Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...

Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the ...

Regeneron is already working with Alnylam on its pre-competitive consortium to sequence DNA from 500,000 people in the UK Biobank database and make the data publicly available to the research ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against Billionaire Mario Gabelli’s other large-cap stock picks with huge upside potential.

Unity’s restructuring comes along with 36-week results from its phase 2b Aspire trial that weighed its investigational eye treatment UBX1325 against Regeneron’s blockbuster Eylea in patients ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Discover the best medical schools in the UK featuring 80 universities across the UK. The UK ranking is derived from the Times Higher Education University Rankings by Subject 2025: Medicine, released ...

Regeneron Pharmaceuticals logged a 0.4% change during today's morning session, and is now trading at a price of $571.03 per share. The S&P 500 index moved -2.0%. REGN's trading volume is 167,455 ...